文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

真实世界肾癌与胃肠间质瘤患者舒尼替尼暴露与疗效及毒性的关系

The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour.
PubMed 文献 · Br J Clin Pharmacol · 2020-05-26

该回顾性观察队列纳入53例转移性肾细胞癌和18例转移性胃肠间质瘤患者,接受舒尼替尼治疗及治疗药物监测指导给药。肾癌患者中达到充分暴露者中位治疗时间32周,未达到者15周(P=0.244);41%患者因毒性减量,减量前舒尼替尼谷浓度总和显著高于无毒性减量者(中位60 ng/mL vs 44 ng/mL;P<0.001)。

要点

  • 真实世界中舒尼替尼毒性减量者暴露显著高于无毒性减量者。
  • 毒性阈值可能低于临床试验既往描述水平。
  • 肾癌充分暴露与更长治疗时间的差异未达统计学显著。

核心结论

  • 真实世界队列中因舒尼替尼毒性需减量者的舒尼替尼暴露显著高于无毒性者。
  • 该队列毒性阈值低于临床试验既往描述水平。

研究设计与样本

  • 回顾性观察队列研究,纳入53例转移性肾细胞癌和18例转移性胃肠间质瘤患者,接受舒尼替尼治疗并接受治疗药物监测指导给药。

主要发现

  • 肾癌达到充分舒尼替尼暴露者(n=39)中位治疗时间32周,未达到者(n=12)15周(P=0.244)。
  • 29例(41%)因毒性减量者减量前舒尼替尼谷浓度总和显著高于无毒性减量者(中位60 ng/mL vs 44 ng/mL;P<0.001)。
  • 减量后谷浓度总和降至与无毒性减量者相当水平(44 ng/mL;P=0.488)。

关键数值与推荐

  • 因毒性减量者减量前舒尼替尼谷浓度总和中位60 ng/mL,无毒性减量者中位44 ng/mL(P<0.001)。
  • 减量后谷浓度总和中位44 ng/mL,与无毒性减量者比较P=0.488。

临床怎么用

  • 真实世界舒尼替尼治疗中可结合治疗药物监测评估暴露与毒性风险。
  • 因毒性减量后暴露可降至与无毒性者相当水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Sunitinib is an oral tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Because of the large interpatient pharmacokinetic variability and established exposure-response and exposure-toxicity relationships in clinical trial patients, therapeutic drug monitoring (TDM) seems promising for optimizing sunitinib exposure. We aimed to investigate the relationship between sunitinib exposure and treatment outcome in a real-world patient cohort. METHODS: We performed a retrospective observational cohort study in 53 patients with metastatic RCC and 18 patients with metastatic GIST treated with sunitinib and receiving TDM-guided dosing. Time on treatment - as a surrogate for progression-free survival - in patients who achieved adequate sunitinib exposure was compared with patients who did not. Additionaly, the median sunitinib exposure was compared in patients with or without sunitinib-induced toxicity leading to dose reduction. RESULTS: The median time on treatment in patients with RCC who achieved adequate sunitinib exposure (n = 39) was 32 weeks, compared to 15 weeks in patients who did not achieve adequate sunitinib exposure (n = 12) (P = 0.244). In 29 patients (41%) with toxicity leading to dose reduction, sunitinib sum plasma trough concentration (Ctrough ) until dose reduction was significantly higher compared to patients without toxicity leading to dose reduction (median 60 ng/mL vs 44 ng/mL; P < 0.001) and reduced to comparable levels after dose reduction (44 ng/mL; P = 0.488). CONCLUSION: In our real-world patient cohort, patients with sunitinib-induced toxicity requiring dose reduction had significantly higher sunitinib exposure compared to patients without toxicity. The threshold for toxicity, however, was lower compared to that previously described in clinical trials.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Westerdijk K, Krens SD, van der Graaf WTA, et al. The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. Br J Clin Pharmacol. 2020. PMID: 32358810. doi:10.1111/bcp.14332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。